TCR peptide therapy in human autoimmune diseases

Area of Science:

• Immunology
• Autoimmune Diseases
• Vaccine Development

Background:

• Inflammatory Th1 cells contribute to autoimmune diseases such as multiple sclerosis (MS), rheumatoid arthritis (RA), and psoriasis.
• Regulatory Th2 cells specific for T cell receptor (TCR) peptides offer a potential therapeutic mechanism.
• These Th2 cells can inhibit pathogenic Th1 cells via a bystander effect.

Purpose of the Study:

• To investigate the potential of TCR peptide vaccination in modulating Th1/Th2 cell responses for autoimmune disease treatment.
• To identify disease-associated TCR V genes in MS, RA, and psoriasis.
• To assess the safety and efficacy of TCR peptide vaccination in patients.

Main Methods:

• Identification of disease-associated TCR V genes (e.g., BV5S2, BV6S5, BV13SI in MS).
• In vivo immunogenicity testing of TCR peptides derived from these genes.
• Administration of TCR peptide vaccines to patients with MS, RA, and psoriasis.
• Monitoring of Th2 cell expansion, cytokine production (e.g., IL-10), and clinical outcomes.

Main Results:

• TCR peptides were consistently immunogenic in vivo.
• Vaccination boosted TCR-reactive Th2 cells, which secreted inhibitory cytokines like IL-10.
• Direct cell-cell contact between Th2 and Th1 cells also induced inhibitory cytokine release.
• TCR peptide vaccination demonstrated safety and tolerability in 824 patients across multiple trials.
• Significant clinical improvement was observed in a subset of patients responding to immunization.

Conclusions:

• TCR peptide vaccination is a safe and well-tolerated approach for autoimmune diseases.
• This strategy effectively activates regulatory Th2 cells to suppress inflammatory Th1 responses.
• TCR peptide vaccination shows promise for treating complex autoimmune conditions like MS, RA, and psoriasis.